MCS110

Phase 2Small molecule

Novartis

MCS110 is one of 92 small molecule programs targeting Synovitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SynovitisActive, not recruiting

Breast CancerActive, not recruiting

MelanomaActive, not recruiting

Prostate CancerActive, not recruiting

SynovitisPhase 2

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

MelanomaPhase 1/Phase 2

Active, not recruiting

Prostate CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adriamycin

GGynecologic Oncology Group

Preclinical

87 2

MCS110

Novartis

Phase 2

3 3

Gemzar

GGynecologic Oncology Group

Preclinical

22 4

Megace

Bristol-Myers Squibb

Preclinical

4 5

Blenoxane

Bristol-Myers Squibb

Preclinical

1 6

Spravato

WWim Janssens

Preclinical

2 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—9

Vfend

PPrism Pharmaceuticals

Preclinical

—10

Perflutren Lipid Microcpheres

TThomas Jefferson University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer3 trials

MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer

Withdrawn·WWashington University School of Medicine·Phase 1·NCT03285607

Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

Completed· Novartis logo

Novartis·Phase 2·NCT02435680·50 enrolled

Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).

Terminated· Novartis logo

Novartis·Phase 1·NCT03742349·64 enrolled

Advanced Malignancies1 trial

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

Completed· Novartis logo

Novartis·Phase 1/2·NCT02807844·141 enrolled

Melanoma1 trial

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

Completed·—·Phase 1/2·NCT03455764·6 enrolled

Synovitis1 trial

MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS)

Completed· Novartis logo

Novartis·Phase 2·NCT01643850·36 enrolled

Prostate Cancer1 trial

A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases

Terminated· Novartis logo

Novartis·Phase 1/2·NCT00757757·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for MCS110. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MCS110 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MCS110. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Novartis

MCS110

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer3 trials

Advanced Malignancies1 trial

Melanoma1 trial

Synovitis1 trial

Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News